Grafa News and Videos — Page 319

CervoMed (NASDAQ:CRVO) reported new Phase 2b analyses linking neflamapimod benefits to low pTau181 levels and sufficient drug exposure in the 159-patient RewinD-LB trial.

Ranger Energy Services (NYSE:RNGR) announced a new agreement to provide three additional ECHO hybrid workover rigs to Hess Corporation (a subsidiary of Chevron (NYSE:CVX)), marking a continued expansion of its electrified rig fleet.

Hemab Therapeutics (NASDAQ:COAG) shared Phase 2 long-term extension data for its drug candidate sutacimig, which demonstrated sustained prophylactic bleed reduction across 34 patients with Glanzmann thrombasthenia.

HCA Healthcare (NYSE:HCA) expects preliminary second-quarter revenue of $20.230 billion, an 8.7% increase from $18.605 billion in the same period of 2025.

IBM (NYSE:IBM) expects preliminary second-quarter revenue of $17.2 billion, up 1% but below analysts’ $17.86 billion estimate.

America’s Car-Mart (NASDAQ:CRMT) reported fiscal 2026 revenue of $1.28 billion and a net loss of $16.79 per share.

Atrium Therapeutics (NASDAQ:RNA) received FDA clearance for its Investigational New Drug application to begin a 37-participant Phase 1/2 clinical trial.

Escalating tensions in the Strait of Hormuz are threatening not only oil supplies but also critical sulphur shipments, with a partial closure of the maritime chokepoint disrupting significant volumes of seaborne sulphur trade, according to a Bloomberg Markets report.

Xanadu (NASDAQ:XNDU) and Lockheed Martin (NYSE:LMT) announced a strategic collaboration to expand internal quantum programming training.

Summit Therapeutics (NASDAQ:SMMT) sold its investigational Phase III precision antibiotic ridinilazole to Biossil for up to $105 million.